Table 2 A summary of the mean outcome scores from the various publications
From: Stem cells for the treatment of early to moderate osteoarthritis of the knee: a systematic review
Score | Author | Year | Number of knees | Modality | K-L Grade | Pre-injection score | Post-injection score | Improvement points | Time of post injection score | Notes (p-values) |
|---|---|---|---|---|---|---|---|---|---|---|
VAS | Garay-Mandoza [7] | 2017 | 26 | BMAC | 2–3 | 5.3 | 0.9 | 4.4 | 6 months | Improved (n.a.) |
Tsubosaka [21] | 2020 | 11 | SVF | 2 | 3.6 | 2.1 | 1.5 | 12 months | Improved (n.a.) | |
Tsubosaka [21] | 2020 | 36 | SVF | 3 | 5.2 | 3.7 | 1.5 | 12 months | Improved (n.a.) | |
Varady [22] | 2020 | 17 | BMAC | 1–3 | 2.7 | 2.1 | 0.6 | 3 months | Improved (p = 0.003) | |
Yokota [27] | 2022 | 30 | SVF | 2–3 | 7.2 | 5 | 2.2 | 2 years | Improved (p < 0.05) | |
Kaszynski [10] | 2022 | 20 | AAT | 2–3 | 5.1 | 2.8 | 2.3 | 12 months | Improved (p < 0.001) | |
Aletto [1] | 2022 | 123 | SVF | 1–3 | 6.5 | 2 | 4.5 | 6 months | Improved (p < 0.05) | |
Zhang [28] (Stem Cell Research & Therapy) | 2022 | 56 | SVF | 2–3 | 4 | 1.8 | 2.2 | 5 years | Improved (p < 0.001) | |
Zhang [29] (BioMed Research International) | 2022 | 29 | SVF | 2 | 4.3 | 0.9 | 3.4 | 12 months | Improved (p < 0.001) | |
Zhang [29] (BioMed Research International) | 2022 | 24 | SVF | 3 | 6 | 0.8 | 5.2 | 12 months | Improved (p < 0.001) | |
WOMAC | Garay-Mandoza [7] | 2017 | 26 | BMAC | 2–3 | 62.6 | 91.7 | 30.1 | 6 months | Improved (n.a.) |
Tsubosaka [21] | 2020 | 11 | SVF | 2 | 27.7 | 11.2 | 16.5 | 12 months | Improved (n.a.) | |
Tsubosaka [21] | 2020 | 36 | SVF | 3 | 35.1 | 26 | 9.1 | 12 months | Improved (n.a.) | |
Garza [8] | 2020 | 13 | SVF | 2–3 | 56.2 | 21.8 | 34.4 | 12 months | Improved (n.a.) | |
Garza [8] | 2020 | 13 | SVFx2 | 2–3 | 47.1 | 13.2 | 33.9 | 12 months | Improved (n.a.) | |
Anz [2] | 2022 | 45 | BMAC | 1–3 | 35.3 | 20.8 | 14.5 | 2 years | Improved (p < 0.01) | |
Kaszynski [10] | 2022 | 20 | AAT | 2–3 | 63.9 | 83.6 | 19.7 | 12 months | Improved (p < 0.001) | |
Zhang [28] (Stem Cell Research & Therapy) | 2022 | 56 | SVF | 2–3 | 33.2 | 27 | 6.2 | 5 years | Improved (p < 0.001) | |
WOMAC Pain | Anz [2] | 2022 | 45 | BMAC | 1–3 | 7 | 3.8 | 3.2 | 2 years | Improved (p < 0.01) |
Zhang [29] (BioMed Research International) | 2022 | 29 | SVF | 2 | 9,4 | 2,7 | 6,7 | 12 months | Improved (p < 0.001) | |
WOMAC Physical Function | Anz [2] | 2022 | 45 | BMAC | 1–3 | 22.9 | 13.2 | 9.7 | 2 years | Improved (p < 0.01) |
Zhang [29] (BioMed Research International) | 2022 | 29 | SVF | 2 | 24.7 | 10.1 | 14.6 | 12 months | Improved (p < 0.001) | |
WOMAC Stiffness | Anz [2] | 2022 | 45 | BMAC | 1–3 | 3.8 | 2.2 | 1.6 | 2 years | Improved (p < 0.01) |
Zhang [29] (BioMed Research International) | 29 | SVF | 2 | 2.8 | 0.9 | 1.9 | 12 months | Improved (p < 0.001) | ||
KOOS | Tsubosaka [21] | 2020 | 11 | SVF | 2 | 52.9 | 68.5 | 15.6 | 12 months | Improved (n.a.) |
Tsubosaka [21] | 2020 | 36 | SVF | 3 | 48.6 | 56.3 | 7.7 | 12 months | Improved (n.a.) | |
Aletto [1] | 2022 | 52 | SVF | 1 | 55.4 | 89.8 | 34.4 | 6 months | Improved (p < 0.05) | |
Aletto [1] | 2022 | 61 | SVF | 2 | 49.9 | 85.9 | 36 | 6 months | Improved (p < 0.05) | |
Aletto [1] | 2022 | 10 | SVF | 3 | 45 | 84.1 | 39.1 | 6 months | Improved (p < 0.05) | |
Yokota [27] | 2022 | 30 | SVF | 2–3 | 40 | 56 | 16 | 2 years | Improved (p < 0.05) | |
KOOS pain | Varady [22] | 2020 | 17 | BMAC | 1–3 | 53.8 | 83 | 29.2 | 3 months | Improved p < 0.001 |
Kaszynski [10] | 2022 | 20 | AAT | 2–3 | 57.8 | 78.9 | 21.1 | 12 months | Improved (p < 0.001) | |
KOOS Symptoms | Varady [22] | 2020 | 17 | BMAC | 1–3 | 50.9 | 74.5 | 23.6 | 3 months | Improved (p = 0.053) |
Kaszynski [10] | 2022 | 20 | AAT | 2–3 | 57.7 | 78.9 | 21.2 | 12 months | Improved (p < 0.001) | |
KOOS ADL | Varady [22] | 2020 | 17 | BMAC | 1–3 | 61.1 | 89.3 | 28.1 | 3 months | Improved p < 0.001 |
Kaszynski [10] | 2022 | 20 | AAT | 2–3 | 63.7 | 84 | 20.3 | 12 months | Improved (p < 0.001) | |
KOOS Sports/Rec | Varady [22] | 2020 | 17 | BMAC | 1–3 | 36.9 | 72.6 | 35.7 | 3 months | Improved (p = 0.006) |
Kaszynski [10] | 2022 | 20 | AAT | 2–3 | 35.5 | 66.1 | 30.6 | 12 months | Improved (p < 0.001) | |
KOOS QOL | Varady [22] | 2020 | 17 | BMAC | 1–3 | 32.7 | 66.1 | 33.4 | 3 months | Improved (p = 0.003) |
Kaszynski [10] | 2022 | 20 | AAT | 2–3 | 38.8 | 62.2 | 23.4 | 12 months | Improved (p < 0.001) | |
KOOS Index | Kaszynski [10] | 2022 | 20 | AAT | 2–3 | 55.7 | 77.9 | 22.2 | 12 months | Improved (p < 0.001) |
KOOS Joint Replacement | Wells [24] | 2020 | 13 | BMAC | 1–2 | 63.1 | 80.3 | 17.2 | 12 months | Improved (p < 0.001) |
IKDC | Kaszynski [10] | 2022 | 20 | AAT | 2–3 | 44.2 | 68.9 | 24.7 | 12 months | Improved (p < 0.001) |
Estrada [3] | 2020 | 33 | SVF | 3 | 33.9 | 64.2 | 30.3 | 12 months | Improved (n.a.) | |
Estrada [3] | 2020 | 27 | BMAC | 3 | 30.2 | 57.6 | 27.4 | 12 months | Improved (n.a.) | |
Lysholm | Varady [22] | 2020 | 17 | BMAC | 1–3 | 55.5 | 77.3 | 21.8 | 3 months | Improved p = 0.009 |
KSS-C | Estrada [3] | 2020 | 33 | SVF | 3 | 38.9 | 65.6 | 26.7 | 12 months | Improved (n.a.) |
Estrada [3] | 2020 | 27 | BMAC | 3 | 33.8 | 56.7 | 22.9 | 12 months | Improved (n.a.) | |
KSS-F | Estrada [3] | 2020 | 33 | SVF | 3 | 53.3 | 76.7 | 23.4 | 12 months | Improved (n.a.) |
Estrada [3] | 2020 | 27 | BMAC | 3 | 52 | 75.6 | 23.6 | 12 months | Improved (n.a.) | |
JKOM | Tsubosaka [21] | 2020 | 11 | SVF | 2 | 27.4 | 11.4 | 16 | 12 months | Improved (n.a.) |
Tsubosaka [21] | 2020 | 36 | SVF | 3 | 37.4 | 31.6 | 5.8 | 12 months | Improved (n.a.) | |
EQ-5D-5L | Kaszynski [10] | 2022 | 20 | AAT | 2–3 | 70 | 80 | 10 | 12 months | Improved p < 0.01 |
Time Up & Go (sec) | Kaszynski [10] | 2022 | 20 | AAT | 2–3 | 6.9 | 5.6 | 1.3 | 12 months | Improved (p < 0.001) |
5 Times Sit to Stand (sec) | Kaszynski [10] | 2022 | 20 | AAT | 2–3 | 10.8 | 8.2 | 2.6 | 12 months | Improved (p < 0.001) |
10 min walk test | Kaszynski [10] | 2022 | 20 | AAT | 2–3 | 6.2 | 4.8 | 1.4 | 12 months | Improved (p < 0.001) |